Pure Mouth Liquid

Description

The drug is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. The tablet is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. Inactive ingredients consist of lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for oral use twice daily, specifically in the morning and evening. The recommended dosage is 10-15 mL per administration. Patients should take the drug into the mouth, swish for approximately 30 seconds, and then rinse and spit out.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The medication is indicated for oral administration only. Healthcare professionals should ensure that patients are instructed to take the medication as directed, adhering strictly to the prescribed dosage regimen. It is essential to confirm that the patient understands the importance of taking the medication by mouth and not through any other route.

Dosing should be individualized based on the patient's specific needs and clinical response. Regular monitoring may be necessary to adjust the dosage as required. It is recommended that healthcare providers provide clear guidance on the timing and frequency of doses to optimize therapeutic outcomes.

Patients should be advised to take the medication with a full glass of water, unless otherwise directed, to facilitate proper absorption.

Contraindications

Use of this product is contraindicated in individuals who are unable to keep it out of reach of children. This precaution is essential to prevent accidental ingestion or misuse by pediatric patients. No other contraindications have been identified in the provided data.

Warnings and Precautions

It is imperative to adhere to the prescribed usage and capacity of the product to ensure safety and efficacy. The use of this product in children should be conducted under the guidance and supervision of a guardian to mitigate any potential risks.

This product is intended solely for use as a mouthwash and must not be ingested or used for internal purposes. Healthcare professionals should emphasize the importance of this restriction to patients and caregivers.

For children under the age of 6, the product should only be used if specifically directed by a pharmacist or physician. This precaution is crucial to prevent any adverse effects associated with inappropriate use in this age group.

Side Effects

Patients should be aware of the following adverse reactions associated with the use of this product.

Serious adverse reactions may occur if the product is not used as prescribed. It is crucial to adhere to the recommended usage and capacity to avoid potential complications. The product is intended solely for use as a mouthwash and should not be ingested or used for internal purposes.

In pediatric populations, the use of this product requires careful consideration. It is advised that children under the age of 6 should not use the product unless directed by a pharmacist or healthcare provider. Additionally, the use of the product in children should always be conducted under the guidance and supervision of a guardian to ensure safety and efficacy.

These precautions are essential to minimize the risk of adverse reactions and to ensure the safe use of the product in all patients, particularly in vulnerable populations such as children.

Drug Interactions

There are no specific drug interactions identified for this medication. Additionally, no laboratory test interactions have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Pure Mouth Liquid (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this medication under the guidance and supervision of a guardian. It is contraindicated for children under 6 years of age unless specifically directed by a pharmacist or physician.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is no specific information available regarding the use of this drug during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment and the need to inform their healthcare provider if they become pregnant or plan to become pregnant while using this medication.

Lactation

There is no specific information regarding the use of PURE MOUTH LIQUID - sodium fluoride liquid in lactating mothers or any lactation considerations provided in the drug insert. Therefore, healthcare professionals should exercise caution and consider the potential risks and benefits when advising lactating mothers about the use of this product. There are no known data on excretion in breast milk or effects on breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or toxicology experts for guidance on specific management protocols and interventions tailored to the substance involved.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective treatment and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the provided text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children to prevent accidental ingestion or misuse. It is important for patients to understand the potential risks associated with improper access to the medication by young children. Providers should encourage patients to store the medication in a secure location and to be vigilant about monitoring its use.

Storage and Handling

The product is supplied in a configuration that ensures safety and efficacy for its intended use. It is essential to keep the product out of reach of children to prevent accidental ingestion. The product is specifically formulated for use as a mouthwash and should not be used for internal purposes.

For children under the age of 6, the product should only be used if directed by a pharmacist or doctor, ensuring that appropriate guidance is followed for safe usage.

Storage conditions should be maintained in a cool, dry place, away from direct sunlight and extreme temperatures, to preserve the integrity of the product. Special handling precautions should be observed to ensure that the product is used only as intended and stored securely.

Additional Clinical Information

Patients should use the product twice a day, in the morning and evening, with a recommended dosage of 10-15 ml per use. The solution should be swished in the mouth for approximately 30 seconds before being spat out.

Clinicians should advise patients to keep the product out of reach of children and to supervise its use in children. It is important to note that the product is intended solely for mouthwash purposes and should not be ingested. Additionally, it should not be used in children under 6 years of age unless directed by a pharmacist or doctor.

Drug Information (PDF)

This file contains official product information for Pure Mouth Liquid, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)